ClinicalTrials.gg
RecruitingNCT07587125RESET-MSUpdated Aug 5, 2026

Safety and Efficacy of S103 Cells in Progressive/Refractory Multiple Sclerosis

A Phase 1 interventional study of S103 cells in Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis and Multiple Sclerosis (MS) Secondary Progressive, sponsored by Xijing Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by Xijing Hospital · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Multiple Sclerosis, Chronic Progressive with a site in China — 4 open to participants now, 6 under way, 2 of them phase 3. Multiple Sclerosis, Chronic Progressive · China.

Planned enrollment
9th of 11
9 · median 60
Started
2026
with 3 others
Phase 1
3 of 12
2 open now
Registered
10th of 12
by date
Lead sponsor
1 of 12
Xijing Hospital

Among the 12 studies in Multiple Sclerosis, Chronic Progressive with a site in China, this one is the 9th largest by planned enrollment of the 11 interventional ones that give a count, is one of 4 that started in 2026, is one of 3 in phase 1, and was the 10th registered.

Multiple Sclerosis, Chronic Progressive

245 studies on the registry are indexed under Multiple Sclerosis, Chronic Progressive; 54 are open to participants now.

Browse Multiple Sclerosis, Chronic Progressive studies →

Open to participants now

4 of the 12 studies in Multiple Sclerosis, Chronic Progressive with a site in China are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 39 Multiple Sclerosis, Chronic Progressive studies recruiting now, 7 (18%) set no upper age limit and 26 (67%) stop at 75 or younger; none take children under 18; 6 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Multiple Sclerosis, Chronic Progressive with a site in China, or all of them as a file.
02

Study summary

This study is a single-center, open-label, single-arm, exploratory clinical study to evaluate the safety, tolerability, and preliminary efficacy of S103(BCMA-CAR T )cells in the treatment of progressive or refractory multiple sclerosis. The study is a dose escalation trial in adult progressive and refractory MS patients. A standard "3+3" design will be used to perform dose escalation to explore the safety profile and dose-limiting toxicities (DLTs). A total of 9 MS patients who meet the inclusion criteria are expected to be recruited.

03

Conditions studied

  • Multiple Sclerosis (MS) Primary Progressive
  • Multiple Sclerosis
  • Multiple Sclerosis (MS) Secondary Progressive
  • Refractory Multiple Sclerosis

Keywords

  • Multiple Sclerosis
  • Progressive Multiple Sclerosis
  • Refractory Multiple Sclerosis
  • BCMA-CAR T Cells
  • Chimeric Antigen Receptor T-Cell Therapy
  • Safety and Efficacy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years and ≤75 years;
  2. The subject signs the form, is willing and able to comply with the protocol, complete the research assessments and return for follow-up;
  3. To be diagnosed with Multiple Sclerosis (MS) according to the 2017 McDonald criteria, specifically including Progressive MS (Primary Progressive MS [PPMS] or Secondary Progressive MS [SPMS]) or Relapsing-Remitting MS (RRMS);
  4. The subject must be assessed by the investigator as having progressive or MS for which no effective standard therapy is available. For subjects with Relapsing MS (RMS), refractory/progressive disease is defined as having experienced at least 2 clinical relapses within the past 2 years, or at least 1 clinical relapse within the past 1 year accompanied by at least one gadolinium-enhancing lesion on MRI within the past year, despite treatment with standard disease-modifying therapies (DMTs). In addition, the subject must have an Expanded Disability Status Scale (EDSS) score between 2.0 and 7.0, inclusive, at both screening and baseline;
  5. Male study participants must agree to take measures during the treatment period and within 1 year after receiving study treatment, and are prohibited from donating sperm throughout the study period;
  6. Women of (WOCBP) must agree to take contraceptive measures during treatment and for at least 1 year after receiving study treatment. Participants must have a negative serum pregnancy test result during screening; a negative urine pregnancy test result must be confirmed before receiving CAR-T for the first time.

Exclusion criteria

Exclusion Criteria:

Subjects will be ineligible for inclusion in the study if they meet any of the following criteria prior to screening or at the baseline visit:

  1. The subject has any medical, psychological, or social condition that, in the investigator's opinion, may harm the subject, interfere with their ability to participate in the study, or result in poor protocol compliance;
  2. Female subjects who are pregnant or lactating, plans to become pregnant at any time within 12 months after receiving CAR-T cell treatment, or has a history of spontaneous or induced abortion within 4 weeks prior to screening;
  3. The subject has a active infection, such as sepsis, pneumonia, or a severe local abscess, or a serious infection requiring hospitalization or intravenous antibiotic treatment within 4 weeks prior to screening. Subjects are also excluded if they have a known immunodeficiency disorder including (HIV), test positive for surface antigen (HBsAg) or detectable Hepatitis B virus (HBV) DNA, test positive for virus (HCV) antibody with detectable HCV RNA, test positive for syphilis during the screening period, or have an active or high-risk history of tuberculosis infection;
  4. The subject has previously received any Chimeric Antigen Receptor (CAR) T-cell therapy or other genetically modified cell therapies, or has a history of hematopoietic stem cell transplantation (HSCT) or solid organ transplantation. Furthermore, subjects are excluded if they have received intravenous immunoglobulin (IVIG) or plasma exchange (PE) within 4 weeks prior to screening, or have received tocilizumab or eculizumab treatment within 3 months prior to screening;
  5. The subject is diagnosed with an active, severe disease other than Multiple Sclerosis, such as Systemic Lupus Erythematosus or Rheumatoid Arthritis. This also includes the presence of other severe progressive neurodegenerative or central nervous system (CNS) disorders, such as Parkinson's disease, Alzheimer's disease, stroke, or active CNS tumors, that the investigator believes would confound the clinical assessment of Multiple Sclerosis. Additionally, a history of active within the past 5 years excludes the subject, with the exception of adequately treated basal cell or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix;
  6. The subject exhibits specific laboratory abnormalities or organ dysfunction during the screening period, including elevated liver enzymes with or ALT greater than 1.5 times the (ULN), total greater than 1.5 times the ULN, or a (CrCl) of less than 60 mL/min. Exclusions also apply for an (ANC) of less than 2.0 × 10\^9/L, a count of less than 100 × 10\^9/L, levels below 100 g/L, or severe cardiovascular or pulmonary diseases, which include a (LVEF) below 50%, unstable angina or myocardial infarction within the past 6 months, or a resting peripheral blood oxygen saturation (SpO2) of 91% or less;
  7. The subject has a known severe allergy, , or intolerance to fludarabine, cyclophosphamide, or any contained in the S103 CAR-T cell product, such as human serum albumin. Subjects are also excluded if they have received any within 6 weeks prior to screening, or plan to receive a live vaccine during the study period.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
9 participants (estimated)

Study arms

  • Experimental
    S103 cells

    subjects will undergo leukapheresis followed by lymphodepletion conditioning with cyclophosphamide and fludarabine, then receive S103 CAR-T cell infusion.

    Drug: S103 cells

Interventions

  • DrugS103 cells

    Dose Level 0 (De-escalation dose): 0.5×10\^6 CAR-T cells/kg Dose Level 1 (Starting dose): 1.0×10\^6 CAR-T cells/kg Dose Level 2 (Maximum dose): 2.0×10\^6 CAR-T cells/kg

06

What researchers measure

Primary outcomes

  1. Incidence and type of Dose-Limiting Toxicities (DLTs)

    A DLTs is defined as any Grade 4 toxicity or Grade 3 toxicity lasting more than 7 days occurring within 28 days after BCMA-CAR T infusion that is related to the treatment (with specific exceptions for manageable CRS, neurotoxicity, and hematologic toxicities as defined in the protocol). This is used to determine the safety and tolerable dose.

    Time frame: From Day 1 up to Day 28 post S103 infusion

  2. Incidence and severity of AEs, including changes in vital signs, physical examination, laboratory parameters, Electrocardiograms and Echocardiograms.

    To evaluate the AEs occurring within 6 months after S103 infusion

    Time frame: From Day 1 up to week 26 post S103 infusion

Secondary outcomes

  1. PD-soluble BCMA

    The changes in concentration of BCMA in the peripheral blood after S103 infusion

    Time frame: From Day 1 up to week 26 post S103 infusion

  2. PK-BCMA CAR-T cells

    The concentration of BCMA-CAR T cells(cells/mL) in peripheral blood after administration was detected by flow cytometry

    Time frame: From Day 1 up to Day 28 post S103 infusion

  3. PD-NFL

    The changes in peripheral blood neurofilament light chain(NfL) concentration in patients with MS

    Time frame: From Day 1 up to week 26 post S103 infusion

  4. PD-OB

    The changes in CSF Oligoclonal Bands index in patients with MS

    Time frame: From Day 1 up to week 26 post S103 infusion

  5. Changes of Expanded Disability Status Scale(EDSS)scores

    The EDSS score ranges from 0 to 10, with higher scores indicating worse disability. A negative change relative to baseline indicates clinical improvement. Disability worsening is defined as follows: an increase of at least 2.0 points if the baseline EDSS score is 0; an increase of at least 1.0 point if the baseline EDSS score is 1.0 to 5.0; and an increase of at least 0.5 points if the baseline EDSS score is 5.5 or higher.

    Time frame: From Day 1 up to week 26 post S103 infusion

Other outcomes

  1. Changes in proportion of peripheral blood immune cell subsets and inflammatory markers levels

    Changes in proportion of peripheral blood immune cell subsets and inflammatory markers levels of subjects after infusion of S103

    Time frame: From Day 1 up to week 26 post S103 infusion

  2. Changes in Cerebrospinal Fluid (CSF) parameters

    Evaluation of central nervous system (CNS) microenvironment changes through lumbar puncture. Parameters include CSF cytology, biochemistry, cytokines, lymphocyte subsets, free kappa light chains, and oligoclonal band (OB) index, and multi-omics analysis of cerebrospinal fluid immune microenvironment

    Time frame: From Day 1 up to week 26 post S103 infusion

  3. MS: Annualized Relapse Rate (ARR)

    Annualized relapse rate (ARR): Number of MS relapses divided by person-years of observation

    Time frame: From Day 1 up to 1 year post S103 infusion

  4. Time to first relapse

    Time from S103 infusion to the first relapse of MS

    Time frame: From Day 1 up to 1 year post S103 infusion

  5. Imaging prognostic evaluation

    Neurological imaging assessments before intervention and at 26 weeks after intervention, including: gadolinium-enhancing lesions, T2, SWI, and other relevant MRI sequences.

    Time frame: At baseline (pre-infusion), Day 28, and week 26 post S103 infusion

  6. Percent of NEDA-3

    The proportion of patients achieving no evidence of disease activity-3 (NEDA-3), defined as no relapse, no disability worsening, and no MRI activity

    Time frame: From Day 1 up to 1 year post S103 infusion

  7. 9-Hole Peg Test (9-HPT)

    Change from baseline in the 9-Hole Peg Test (9-HPT), measured in seconds. A higher value indicates worse upper extremity function. A negative change from baseline indicates improvement.

    Time frame: At baseline (pre-infusion), Month 1, Month 3, and Month 6 post S103 infusion

  8. Change in Timed 25-Foot Walk (T25-FW) Time

    Change from baseline in the Timed 25-Foot Walk (T25-FW), measured in seconds. A higher value indicates worse ambulatory function. A negative change from baseline indicates improvement.

    Time frame: At Baseline (pre-infusion), Month 1, Month 3, and Month 6 post S103 infusion

  9. Change in Mini-Mental State Examination (MMSE) Score

    Change from baseline in the Mini-Mental State Examination (MMSE) score. Scores range from 0 to 30, with higher scores indicating better cognitive function. A positive change from baseline indicates improvement.

    Time frame: At Baseline (pre-infusion), Month 1, Month 3, and Month 6 post S103 infusion

  10. Change in Montreal Cognitive Assessment (MoCA) Score

    Change from baseline in the Montreal Cognitive Assessment (MoCA) score. Scores range from 0 to 30, with higher scores indicating better cognitive function. A positive change from baseline indicates improvement.

    Time frame: At Baseline (pre-infusion), Month 1, Month 3, and Month 6 post S103 infusion

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Nov 2027, 18 months after the start.

Of 21 phase 1 interventional studies under Multiple Sclerosis, Chronic Progressive, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's planned 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2026
First posted
May 14, 2026
StartActual
May 8, 2026
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2029
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07587125
Lead sponsor
Xijing Hospital
Collaborators
Hebei Senlang Biotechnology Co., LTD
Responsible party
Sponsor
First posted
May 14, 2026
Start date
May 8, 2026
Primary completion
Nov 2027 (estimated)
Completion
Nov 2029 (estimated)
Last update
Aug 5, 2026

Study contacts

Wen Jiang Dr.
Contact
jiangwen@fmmu.edu.cn
86 29 84771319
Xiaodan Shi Dr.
Contact
Shixd999@163.com
+86 29 84771319

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion